Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazuki Nishimura

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
BJU International|September 13, 2022
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinomaTaizo Uchimoto, Tatsuo Fukushima, Kazumasa Komura, et al.
Clinical and Translational Radiation Oncology|December 22, 2022
Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survivalKeita Nakamori, Shogo Yamazaki, Kazumasa Komura, et al.
Molecular Cancer|November 19, 2023
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder CancerKazumasa Komura, Kensuke Hirosuna, Satoshi Tokushige, et al.
Cancers|November 26, 2022
Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus NivolumabYusuke Yano, Takaya Ohno, Kazumasa Komura, et al.
Cancer Medicine|September 14, 2023
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancerTakuya Tsujino, Satoshi Tokushige, Kazumasa Komura, et al.
Clinical Genitourinary Cancer|October 25, 2023
Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective StudyTakuhisa Nukaya, Kiyoshi Takahara, Atsuhiko Yoshizawa, et al.
Anticancer Research|September 26, 2025
Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial CarcinomaKyosuke Nishio, Kensuke Hirosuna, Taizo Uchimoto, et al.
Japanese Journal of Clinical Oncology|February 3, 2026
Age-stratified clinical outcomes and adverse events in patients with metastatic castration-sensitive prostate cancer receiving triplet therapy with darolutamide, androgen deprivation therapy, and docetaxelTaizo Uchimoto, Kensuke Hirosuna, Heima Niigawa, et al.
World Journal of Urology|November 4, 2023
Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinomaTakuya Tsujino, Kazumasa Komura, Teruo Inamoto, et al.
The Prostate|March 15, 2026
The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line ARPI TherapyTakeshi Tsutsumi, Shogo Yamazaki, Takuya Matsuda, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
BJU International|September 13, 2022
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinomaTaizo Uchimoto, Tatsuo Fukushima, Kazumasa Komura, et al.
Clinical and Translational Radiation Oncology|December 22, 2022
Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survivalKeita Nakamori, Shogo Yamazaki, Kazumasa Komura, et al.
Molecular Cancer|November 19, 2023
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder CancerKazumasa Komura, Kensuke Hirosuna, Satoshi Tokushige, et al.
Cancers|November 26, 2022
Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus NivolumabYusuke Yano, Takaya Ohno, Kazumasa Komura, et al.
Cancer Medicine|September 14, 2023
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancerTakuya Tsujino, Satoshi Tokushige, Kazumasa Komura, et al.
Clinical Genitourinary Cancer|October 25, 2023
Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective StudyTakuhisa Nukaya, Kiyoshi Takahara, Atsuhiko Yoshizawa, et al.
Anticancer Research|September 26, 2025
Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial CarcinomaKyosuke Nishio, Kensuke Hirosuna, Taizo Uchimoto, et al.
Japanese Journal of Clinical Oncology|February 3, 2026
Age-stratified clinical outcomes and adverse events in patients with metastatic castration-sensitive prostate cancer receiving triplet therapy with darolutamide, androgen deprivation therapy, and docetaxelTaizo Uchimoto, Kensuke Hirosuna, Heima Niigawa, et al.
World Journal of Urology|November 4, 2023
Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinomaTakuya Tsujino, Kazumasa Komura, Teruo Inamoto, et al.
The Prostate|March 15, 2026
The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line ARPI TherapyTakeshi Tsutsumi, Shogo Yamazaki, Takuya Matsuda, et al.
Pageof 7